Cannabis for Chronic Pain, Arthritis & Opioid Sparing | CĒD Clinic
Cannabis for Chronic Pain, Arthritis & Opioid Sparing: Clinical Insights
Dr. Benjamin Caplan examines the receptor mechanics of cannabinoid analgesia, peripheral CB2 anti-inflammatory signaling, and peer-reviewed opioid-reduction protocols.
🔥 Nociceptive vs. Neuropathic Pain
Standard opiates often fail against neuropathic nerve pain (burning, tingling, lancinating pain). Cannabinoids engage both central CB1 receptors and peripheral CB2 immune receptors, inhibiting glial cell activation.
💊 Synergistic Opioid-Sparing Ratio
Preclinical and observational studies demonstrate that cannabinoids potentiate opioid analgesia. Patients can often achieve equal or superior pain control with 40% to 60% lower opioid doses, reducing overdose and dependency hazards.
🌿 Anti-Inflammatory β-Caryophyllene
This common dietary terpene functions as a selective CB2 receptor agonist without psychoactivity, suppressing pro-inflammatory cytokine production (TNF-α, IL-6) in arthritic joint capsules.
60-Second Chronic Pain, Arthritis & Nerve Pain Reels
Clinical insights into central sensitization, joint inflammation, and opioid-sparing synergistic protocols.
